CoChat

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

Open access
Ott, Patrick A., Hamid, Omid, Pavlick, Anna C., Kluger, Harriet, Kim, Kevin B., Boasberg, Peter D., Simantov, Ronit, Crowley, Elizabeth, Green, Jennifer A., Hawthorne, Thomas, Davis, Thomas A., Sznol, Mario, Hwu, Patrick · 2014 · Journal of Clinical Oncology
Cited by 97

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: The antibody-drug conjugate glembatumumab vedotin links a fully human immunoglobulin G2 monoclonal antibody against the melanoma-related glycoprotein NMB (gpNMB) to the potent cytotoxin monomethyl auristatin E. This study evaluated the safety and activity of glembatumumab vedotin in patients with advanced melanoma. Patients and Methods: Patients received glembatumumab vedotin every 3 weeks (schedule 1) in a dose escalation and phase II expansion at the maximum-tolerated dose (MTD). Dosing during 2 of 3 weeks (schedule 2) and weekly (schedule 3) was also assessed. The primary end points were safety and pharmacokinetics. The secondary end points included antitumor activity, gpNMB expression, and immunogenicity. Results: One hundred seventeen patients were treated using schedule 1 (n = 79), schedule 2 (n = 15), or schedule 3 (n = 23). The MTDs were 1.88, 1.5, and 1.0 mg/kg for schedules 1, 2, and 3, respectively. Grade 3/4 treatment-related toxicities that occurred in two or more patients included rash, neutropenia, fatigue, neuropathy, arthralgia, myalgia, and diarrhea. Three treatment-related deaths (resulting from pneumococcal sepsis, toxic epidermal necrolysis, and renal failure) occurred at doses exceeding the MTDs. In the schedule 1 phase II expansion cohort (n = 34), five patients (15%) had a partial response and eight patients (24%) had stable disease for ≥ 6 months. The objective response rate (ORR) was 2 of 6 (33%) for the schedule 2 MTD and 3 of 12 (25%) for the schedule 3 MTD. Rash was correlated with a greater ORR and improved progression-free survival. Conclusion: Glembatumumab vedotin is active in advanced melanoma. The schedule 1 MTD (1.88 mg/kg once every 3 weeks) was associated with a promising ORR and was generally well tolerated. More frequent dosing was potentially associated with a greater ORR but increased toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.54.8115

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. 10.1056/NEJMoa1200694 · DOI · Paper page
  2. 10.1056/NEJMoa1103782 · DOI · Paper page
  3. 10.1056/NEJMoa1002011 · DOI · Paper page
  4. 10.1056/NEJMoa1203421 · DOI · Paper page
  5. 10.1056/NEJMoa1003466 · DOI · Paper page
  6. 10.1056/NEJMoa1200690 · DOI · Paper page
  7. 10.1002/ijc.2910600111 · DOI · Paper page
  8. 10.1158/1078-0432.CCR-05-2018 · DOI · Paper page
  9. 10.1074/jbc.M008539200 · DOI · Paper page
  10. 10.4049/jimmunol.178.10.6557 · DOI · Paper page
  11. 10.1615/CritRevEukaryotGeneExpr.v13.i24.180 · DOI
  12. 10.1016/j.febslet.2008.03.030 · DOI · Paper page
  13. 10.1158/1078-0432.CCR-09-1611 · DOI · Paper page
  14. 10.1158/1078-0432.CCR-05-2797 · DOI · Paper page
  15. 10.1158/1541-7786.MCR-07-0119 · DOI · Paper page
  16. 10.1074/jbc.M211498200 · DOI · Paper page
  17. 10.1016/S0168-8278(03)00361-1 · DOI
  18. 10.1371/journal.pone.0012093 · DOI · Paper page
  19. 10.1038/nbt832 · DOI · Paper page
  20. 10.1021/bc800289a · DOI · Paper page
  21. 10.1093/protein/gzl013 · DOI · Paper page
  22. 10.1007/s00280-007-0490-z · DOI
  23. 10.1093/jnci/89.15.1138 · DOI · Paper page
  24. 10.1007/s002800050726 · DOI
  25. 10.1111/apm.12107 · doi:10.1111/apm.12107
  26. 10.1038/srep00573 · DOI · Paper page
  27. 10.1200/JCO.2010.29.5865 · DOI · Paper page
  28. 10.1200/JCO.2011.40.5902 · DOI · Paper page
  29. 10.1056/NEJMoa1002965 · DOI · Paper page
  30. Williams MD, 2010, Melanoma Res, 20, 184, 10.1097/CMR.0b013e3283364a08 · DOI
  31. 10.2215/CJN.03390509 · DOI · Paper page
  32. 10.1182/blood-2006-11-053769 · DOI · Paper page
  33. 10.4049/jimmunol.179.9.5778 · DOI · Paper page
  34. 10.1158/0008-5472.CAN-09-2538 · DOI · Paper page
  35. 10.1002/eji.201041233 · DOI
  36. 10.1158/0008-5472.SABCS12-P6-10-01 · DOI
  37. 10.1158/1535-7163.TARG-13-C232 · doi:10.1158/1535-7163.targ-13-c232
  38. 10.1016/j.molonc.2008.02.002 · DOI
  39. 10.1371/journal.pone.0061895 · DOI · Paper page
  40. 10.1593/tlo.12280 · DOI · Paper page

Cited by

See all 97

Metadata

Authors
Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E., Green, J. A., Hawthorne, T., Davis, T. A., Sznol, M., & Hwu, P.
Venue
Journal of Clinical Oncology
Published
2014-11-10
Volume
32
Issue
32
Pages
3659-3666
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2005354746
Cited by
97
References
4
FWCI
4.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.